MADRID, October 22, 2026 — A late‑stage trial of a personalized mRNA vaccine for melanoma has shown a 42 % lower risk of cancer recurrence or death when added to the standard immunotherapy Keytruda, researchers reported on Thursday.
Breakthrough Trial Results
The study enrolled 1,137 patients with high‑risk melanoma who had undergone surgical removal of their tumors. Participants received the experimental vaccine, intismeran autogene, together with pembrolizumab (Keytruda), while a control group received Keytruda alone. According to a CNN report, the combination cut the risk of recurrence or death by 42 % compared with Keytruda alone.
Dr. Michael Postow, chief of the melanoma service at Memorial Sloan Kettering Cancer Center, described the outcome as “something we’ve never really seen before in terms of the efficacy that it has demonstrated and the way that it works.” The data will be presented at the European Society for Medical Oncology meeting in Madrid.
The trial’s findings have been accepted for publication in the New England Journal of Medicine, and the developers said they are engaging with regulatory authorities to seek U.S. Food and Drug Administration approval.
From Covid Shots to Cancer Vaccines
The technology behind intismeran autogene builds on the mRNA platform that powered Moderna’s Covid‑19 vaccines. As noted by Nine.com.au, the same Nobel‑prize‑winning approach that taught the immune system to recognize a viral spike protein is now being repurposed to teach it to recognize cancer cells. This shift from infectious disease to oncology has been a focus of biotech research for the past decade.
Moderna’s CEO Stéphane Bancel has long argued that mRNA could enable treatments uniquely matched to each patient’s tumor. The current trial provides the first large‑scale clinical evidence that the concept can work in a real‑world setting.
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, called the results “really encouraging” and noted that a decade ago such a vaccine would have been considered fiction. She added that the data represent a milestone on the path toward broader use of personalized mRNA therapies.
How the Personalized Vaccine Works
After a melanoma is surgically removed, a sample of the tumor is sequenced to identify its unique set of neoantigens—mutated proteins that the immune system can recognize as foreign. The vaccine is then custom‑designed to encode mRNA strands that instruct the body’s cells to produce these neoantigens, effectively flagging the cancer for immune attack.
Because each vaccine is tailored to the individual’s tumor profile, it targets only the mutations present in that patient’s disease. Postow explained that this “targeted immune boost” directs the body’s defenses precisely at the cancer cells, reducing collateral activation of the broader immune system.
The approach differs from traditional adjuvant therapy, which typically relies on drugs that broadly stimulate immune checkpoints or deliver chemotherapy. In the melanoma setting, standard adjuvant treatment after surgery has been pembrolizumab alone, a checkpoint inhibitor that prevents cancer cells from evading immune detection. The personalized vaccine adds a second, highly specific layer of immune training.
Clinical Numbers and What They Mean
Beyond the overall 42 % risk reduction, the trial also showed a 38 % lower chance of metastasis or death when the vaccine was added to pembrolizumab, according to Moderna and Merck’s data released to Scientific American. These figures reflect a median follow‑up of about two years.
Two‑year recurrence‑free survival further illustrates the benefit. Nine.com.au reported that 82 % of patients who received the vaccine remained free of melanoma at two years, compared with 70 % in the Keytruda‑only group. The difference suggests a meaningful extension of disease‑free time for many high‑risk patients.
While overall survival data are still pending, the early findings suggest that a personalized mRNA boost can improve the durability of response achieved with checkpoint inhibition alone. The trial also demonstrated that the vaccine was well tolerated, with side‑effect profiles comparable to those of standard immunotherapy.
Next Steps and Broader Implications
Moderna and Merck are now discussing filing for FDA approval, and they are testing the same platform in other cancers, including lung and pancreatic tumors. The success in melanoma provides a template for expanding personalized mRNA vaccines to additional indications.
The study was led internationally by Professor Georgina Long of the Melanoma Institute Australia, who described the results as “a very, very big leap forward in cancer.” Her leadership underscores the collaborative nature of the research, which combined expertise from academia, biotech, and clinical centers worldwide.
For patients and families facing the financial and emotional burden of melanoma, the data offer a hopeful new option that could reduce the need for prolonged, costly treatments if recurrence is prevented. Insurance coverage decisions will likely hinge on the upcoming regulatory filings and the eventual pricing strategy of the vaccine.
As the medical community awaits the full survival analysis, the encouraging part of the story is that a technology once reserved for a global pandemic is now being harnessed to fight a deadly cancer. Patients should discuss emerging treatment options with their oncologists and consider enrollment in clinical trials when appropriate.
Personalized mRNA vaccines represent a shift toward therapies that are matched to the genetic fingerprint of each tumor, offering a more precise and potentially less toxic alternative to conventional adjuvant regimens. While more data are needed, the current evidence suggests a meaningful step forward in the fight against melanoma.
Consult your doctor to understand whether a personalized vaccine trial might be suitable for you or a loved one, and to explore how emerging therapies could fit into your overall treatment plan.
Sources
- Experimental mRNA vaccine cuts risk melanoma returns by 42% | CNN
- Here’s what Moderna’s latest mRNA cancer vaccine data actually show
- Australia helps develop world-first vaccine for melanoma
Photo: Spencerbdavis (CC BY 4.0)
